The pooled results based on 7 included studies for -969(CA) repeat (comprising 7,024 cases and 8,519 controls) and 6 eligible studies for IGF1 rs35767C>T (comprising 3,434 cases and 5,698 controls) indicated that no significant association between these polymorphisms and CRC risk was found in any of the comparisons studied (Table 6). This evidence concerns the gene IGF1 and colorectal carcinoma.